Clinical trials: Eczema/Atopic Dermatitis
Atopic Dermatitis
A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3033 in subjects with moderate-to-severe atopic dermatitis…
- Trial name
- NCT07549984
- Testing
- IBI3033
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Atopic Dermatitis
The Effect of Gladskin on Disease Severity and the Skin Microbiome, Including Staphylococcus Aureus, in Patients With Atopic Dermatitis
Colonization with Staphylococcus aureus is related to inflammation in atopic dermatitis. Gladskin is a product for topical use containing the proprietary enzyme Staphefekt SA.100, which has the ability to specifically lyse the…
- Trial name
- NCT02840955
- Testing
- Staphefekt SA.100
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Atopic Dermatitis
Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response
This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis who require systemic treatment.
- Trial name
- DermAtOmics (NCT05692843)
- Testing
- Cyclosporin A, Follow-up of Cyclospoin treatment already started
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Atopic Dermatitis
A Phase 2 Study of E6005 in Patients With Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety profiles of E6005 ointment in patients with atopic dermatitis compared to vehicle. The pharmacokinetic profile after topical application of E6005 is also assessed.
- Trial name
- NCT01461941
- Testing
- E6005, E6005 ointment (vehicle)
- Where
- 10 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Organon and Co
Atopic Dermatitis, Skin Condition
Clinical Study of Partially Hydrolysed Protein Infant Formula on Trans-epidermal Water Loss (TEWL)
This is a single-centre, prospective, randomized, open-label, controlled trial of 200 infants 42±7 days of age. Subjects will be randomized to one of two open label feeding intervention group: Intact Cow's Milk Protein Formula…
- Trial name
- NCT04763512
- Testing
- Intact Cow's Milk Protein Formula, Partially Hydrolysed Whey Formula
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
The study will assess the safety, pharmacokinetics (PK), and efficacy of different doses of roflumilast (ARQ-151) cream (0.05% and 0.15%) vs placebo applied once daily (QD) for 28 days by adolescents and adults with atopic…
- Trial name
- NCT03916081
- Testing
- Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream
- Where
- 20 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis, which is also known as atopic eczema, is a common inflammatory and chronic skin disease that is characterized by severe recurrent erythematous and pruritic lesions.
- Trial name
- NCT05969730
- Testing
- Baricitinib 4 MG, Azathioprine 1.5-2.5 mg/kg
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Mazandaran University of Medical Sciences
Atopic Dermatitis
Indigo Naturalis in Treating Atopic Dermatitis Topically
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that most commonly occurs in children. The aims of this project are: 1. To evaluate the efficacy of indigo naturalis ointment in treating AD topically; 2.
- Trial name
- NCT02669888
- Testing
- Indigo naturalis ointment
- Where
- 3 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- Chang Gung Memorial Hospital
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
- Trial name
- NCT06787586
- Testing
- ATTO-1310
- Where
- 17 sites in United States, Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Psoriasis, Atopic Dermatitis
Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.
- Trial name
- NCT03381625
- Testing
- BMX-010
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- BioMimetix JV, LLC
Atopic Dermatitis, Psoriasis
Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
The clinical study investigates the long-term course of disease in patients with chronic inflammatory skin diseases (atopic eczema and psoriasis) and the impact of tarheted therapies on the clinical and molecular level.
- Conditions
- Atopic Dermatitis, Psoriasis, Healthy
- Trial name
- DiTrAP (NCT03361215)
- Testing
- Biosampling for molecular analysis
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Eczema, Infantile, Eczema
Seal, Stopping Eczema and Allergy Study
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age.
- Conditions
- Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
- Trial name
- NCT03742414
- Testing
- Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 398 people
- Sponsor
- Kari Nadeau, MD, PhD
Atopic Dermatitis
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side…
- Trial name
- NCT04922021
- Testing
- LEO 138559
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Polymorphic Light Eruption, Psoriasis
Regulatory T Cells (Tregs) in Polymorphic Light Eruption
Polymorphic light eruption (PLE) is a photodermatosis with an extremely high prevalence, particularly among young women (up to 20%).
- Conditions
- Polymorphic Light Eruption, Psoriasis, Atopic Eczema
- Trial name
- NCT00555178
- Where
- 2 sites in Austria
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Atopic Dermatitis (AD)
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
To investigate the efficacy of 0.3% OPA-15406 ointment when administered twice daily for 4 weeks in infants younger than 2 years of age with Atopic Dermatitis
- Trial name
- NCT05372653
- Testing
- OPA-15406
- Where
- Japan
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Atopic Dermatitis
URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis
The goal of this clinical study is to determine whether URGO FilmoCream Eczema is effective as a non-steroidal treatment to relieve symptoms of atopic dermatitis.
- Trial name
- GERONIMO (NCT07295678)
- Testing
- Treatment period with dermocorticoid alone, Treatment period with combination of URGO FilmoCream Eczema and dermocorticoid, Follow-up period after treatment with URGO Filmocream Eczema associated with dermocorticoid
- Where
- 2 sites in Poland
- Volunteers
- 44 people
- Sponsor
- CEN Biotech
Eczema
Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota
This exploratory study aims to investigate the prebiotic potential of daily application of an omega-3 serum and cream to skin affected by eczema. The study will also collect data on any potential adverse effects of the products.
- Trial name
- COS-PBP-03 (NCT07583121)
- Testing
- Omega-3 monoglyceride based topical treatment
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- SCF Pharma
Atopic Dermatitis
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male volunteers and Japanese participants with…
- Trial name
- NCT04211415
- Testing
- DS-2741a
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked.
- Trial name
- DISCOVER (NCT05590585)
- Testing
- dupilumab, Topical emollient (moisturizer)
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.